{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:08:23Z","timestamp":1777514903471,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Actinic keratosis (AK) lesions have the potential to develop into invasive squamous cell carcinomas (SCCs), and approaches to treatment are evolving to try to reduce the burden of SCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To present the published clinical research surrounding the use of 0.5% 5-fluorouracil with 10% salicylic acid (low-dose 5-FU\/SA) for the treatment of hyperkeratotic AKs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A review of published clinical evidence for low-dose 5-FU\/SA for the treatment of AKs. The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Combining low-dose 5-FU with keratolytic SA is associated with high rates of histologic clearance, reduction in lesion number\/area, and sustained clinical response in clinical study and the clinical practice setting. Low-dose 5-FU\/SA has also been evaluated using imaging to detect the progression of subclinical AK lesions through a course of the field-directed treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Low-dose 5-FU\/SA is an effective and well-tolerated treatment option licensed for the lesion-directed treatment of mild-to-moderate hyperkeratotic AK lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1203475416659259","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T22:54:29Z","timestamp":1469141669000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Low-Dose 0.5% 5-Fluorouracil\/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses"],"prefix":"10.1177","volume":"20","author":[{"given":"Pedro","family":"Herranz","sequence":"first","affiliation":[{"name":"Department of Dermatology, La Paz University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Morton","sequence":"additional","affiliation":[{"name":"Forth Valley Dermatology Centre, Stirling Community Hospital, NHS Forth Valley, Stirling, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[{"name":"Private Dermatological Practice Centre, Wuppertal, and Faculty of Health, Witten\/Herdecke University, Witten, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario Rodr\u00edguez","family":"Azeredo","sequence":"additional","affiliation":[{"name":"Almirall S.A., Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Rold\u00e1n-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad Nacional Aut\u00f3noma de M\u00e9xico, and Hospital San Angel Inn Universidad, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"bibr1-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdt032"},{"key":"bibr2-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"bibr3-1203475416659259","doi-asserted-by":"publisher","DOI":"10.2165\/11589300-000000000-00000"},{"key":"bibr4-1203475416659259","unstructured":"Instituto National de Cancerolog\u00eda (INCan). Main causes of outpatients consultations in 2014. http:\/\/incan-mexico.org\/incan\/incan.jsp?iu_p=\/incan\/pub\/estatico\/direccion\/incan-numeros.xml. Accessed March 18, 2015."},{"key":"bibr5-1203475416659259","first-page":"651","volume":"18","author":"Stockfleth E","year":"2008","journal-title":"Eur J Dermatol"},{"key":"bibr6-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"bibr7-1203475416659259","unstructured":"Lucas R, McMichael T, Smith W, Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Environmental Burden of Disease Series. No. 13. www.who.int\/uv\/publications\/solaradgbd\/en\/. Accessed January 27, 2015."},{"key":"bibr8-1203475416659259","first-page":"336","volume":"10","author":"Jones MPFF","year":"2006","journal-title":"Int J Pharm Compd"},{"key":"bibr9-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12833"},{"key":"bibr10-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11085.x"},{"key":"bibr11-1203475416659259","first-page":"466","volume":"11","author":"Davis SA","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"bibr12-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962012000300012"},{"key":"bibr13-1203475416659259","first-page":"17","volume":"147","author":"D\u00edaz-Gonz\u00e1lez JM","year":"2011","journal-title":"Gac Med Mex"},{"key":"bibr14-1203475416659259","doi-asserted-by":"publisher","DOI":"10.4161\/derm.22519"},{"key":"bibr15-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12848"},{"key":"bibr16-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q"},{"key":"bibr17-1203475416659259","first-page":"573","volume":"145","author":"Colombo GL","year":"2010","journal-title":"G Ital Dermatol Venereol"},{"key":"bibr18-1203475416659259","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy and safety of Actikerall\u00ae solution in patients with grade I-II actinic keratoses. NCT02289768. Accessed January 12, 2016."},{"key":"bibr19-1203475416659259","unstructured":"Actikerall summary of product characteristics. www.medicines.org.uk\/emc\/medicine\/24614\/SPC\/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution\/. Accessed January 27, 2015."},{"key":"bibr20-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70113-G"},{"key":"bibr21-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0049-y"},{"key":"bibr22-1203475416659259","unstructured":"Meda Pharmaceuticals. Efudix cream: summary of product characteristics. http:\/\/www.medicines.org.uk\/EMC\/medicine\/6219\/SPC\/Efudix+Cream\/."},{"key":"bibr23-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80077-1"},{"key":"bibr24-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2009.07293_supp.x"},{"key":"bibr25-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10387.x"},{"key":"bibr26-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2012.1707"},{"key":"bibr27-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12702"},{"key":"bibr28-1203475416659259","first-page":"430","volume":"13","author":"Szeimies RM","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"bibr29-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1159\/000365070"},{"key":"bibr30-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004415.pub2"},{"key":"bibr31-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07865.x"},{"key":"bibr32-1203475416659259","volume-title":"Presented at the 1st International Symposium on Cancers of the Skin","author":"Malvehy J"},{"key":"bibr33-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1159\/000370148"},{"key":"bibr34-1203475416659259","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13304"},{"key":"bibr35-1203475416659259","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1860"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475416659259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475416659259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475416659259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:53:33Z","timestamp":1777391613000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475416659259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1177\/1203475416659259"],"URL":"https:\/\/doi.org\/10.1177\/1203475416659259","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]}}}